Lab
Axis Professional Labs LLC
Axis Professional Labs LLC was paid $459K by Medicaid between Jan 2019 and Jul 2023, across 101 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 40% of everything it billed.
33Billing provider infoAXIS PROFESSIONAL LABS LLC
FARMERS BRANCH, TX 75244
FARMERS BRANCH, TX 75244
33aNPI1255879763assigned 02/03/2017
33bProvider typeClinical Medical Laboratory
28Total paid$459K
24GClaims109,327
24DCodes billed101
24AFirst – last monthJan 2019 – Jul 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#91 of 436
Median peer was paid$17K
This provider vs. median27×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 19,381 | $74K | |
| 2020 | 17,596 | $46K | |
| 2021 | 42,169 | $204K | |
| 2022 | 21,919 | $121K | |
| 2023 | 8,262 | $15K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 40% | 5,980 | 3,483 | $183K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 7.2% | 5,518 | 3,400 | $33K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 6.9% | 3,276 | 3,036 | $32K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 6.6% | 2,502 | 2,200 | $30K |
| 86769 | 4.9% | 918 | 893 | $22K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.6% | 342 | 283 | $17K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.4% | 3,728 | 3,451 | $11K |
| 80050 | General health panel | 2.1% | 1,232 | 1,099 | $10K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.0% | 3,201 | 2,938 | $9K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.4% | 49 | 47 | $7K |
| 84403 | 1.3% | 1,623 | 1,519 | $6K | |
| 82607 | 1.2% | 2,275 | 2,111 | $5K |
89 more codes
| 80061 | Lipid panel | 1.2% | 4,608 | $5K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.1% | 665 | $5K |
| 82670 | 1.1% | 1,419 | $5K | |
| 84270 | 1.0% | 1,491 | $5K | |
| 84481 | <1% | 2,018 | $4K | |
| 83002 | <1% | 1,401 | $4K | |
| 83001 | <1% | 1,421 | $4K | |
| 84144 | <1% | 1,310 | $4K | |
| 84146 | <1% | 1,467 | $3K | |
| 82533 | <1% | 1,533 | $3K | |
| 82746 | <1% | 1,887 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 724 | $3K |
| 86800 | <1% | 1,756 | $3K | |
| 86376 | <1% | 1,840 | $3K | |
| 82728 | <1% | 1,945 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,791 | $3K |
| 84466 | <1% | 1,913 | $3K | |
| 86141 | <1% | 1,540 | $3K | |
| 83525 | <1% | 1,579 | $2K | |
| 82172 | <1% | 1,275 | $2K | |
| 84134 | <1% | 129 | $2K | |
| 84436 | <1% | 1,988 | $2K | |
| 83540 | <1% | 2,102 | $2K | |
| 83690 | <1% | 1,540 | $1K | |
| 84479 | <1% | 1,765 | $1K | |
| 82627 | <1% | 1,183 | $1K | |
| 82150 | <1% | 1,539 | $1K | |
| 82610 | <1% | 1,309 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,060 | $1K |
| 80053 | Comprehensive metabolic panel | <1% | 4,124 | $1K |
| 83090 | <1% | 1,075 | $1K | |
| 84550 | <1% | 1,679 | $1K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,233 | $924.27 |
| 83735 | <1% | 1,589 | $638.35 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 313 | $612.04 |
| 86431 | <1% | 1,491 | $465.71 | |
| 83615 | <1% | 1,370 | $442.95 | |
| 82977 | <1% | 1,248 | $386.82 | |
| 84153 | <1% | 314 | $360.19 | |
| 84100 | <1% | 1,397 | $286.20 | |
| 85045 | <1% | 1,310 | $278.91 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 13 | $273.60 |
| 82248 | <1% | 1,203 | $223.66 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 59 | $197.61 |
| 84439 | <1% | 356 | $195.87 | |
| 87631 | <1% | 87 | $188.28 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 338 | $158.86 |
| 84702 | <1% | 307 | $112.40 | |
| 82043 | <1% | 423 | $89.19 | |
| 82570 | <1% | 338 | $66.00 | |
| 82105 | <1% | 15 | $31.32 | |
| 81003 | <1% | 78 | $19.55 | |
| 86140 | <1% | 58 | $13.00 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 582 | $12.06 |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 0% | 3,026 | $0.00 |
| 81227 | 0% | 12 | $0.00 | |
| 81240 | 0% | 12 | $0.00 | |
| 0033U | 0% | 12 | $0.00 | |
| 81231 | 0% | 12 | $0.00 | |
| 81407 | 0% | 91 | $0.00 | |
| 0031U | 0% | 12 | $0.00 | |
| 81410 | 0% | 90 | $0.00 | |
| 81230 | 0% | 12 | $0.00 | |
| 81225 | 0% | 12 | $0.00 | |
| 81226 | 0% | 12 | $0.00 | |
| 82784 | 0% | 50 | $0.00 | |
| 87500 | 0% | 14 | $0.00 | |
| 87640 | 0% | 14 | $0.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 14 | $0.00 |
| 36416 | 0% | 14 | $0.00 | |
| 81408 | 0% | 91 | $0.00 | |
| 81413 | 0% | 90 | $0.00 | |
| 0032U | 0% | 12 | $0.00 | |
| 81414 | 0% | 88 | $0.00 | |
| 81401 | 0% | 133 | $0.00 | |
| 81403 | 0% | 85 | $0.00 | |
| 81442 | 0% | 90 | $0.00 | |
| 81335 | 0% | 12 | $0.00 | |
| 87653 | 0% | 14 | $0.00 | |
| 81405 | 0% | 91 | $0.00 | |
| 81404 | 0% | 102 | $0.00 | |
| 81241 | 0% | 12 | $0.00 | |
| 81328 | 0% | 12 | $0.00 | |
| 81406 | 0% | 91 | $0.00 | |
| 81411 | 0% | 90 | $0.00 | |
| 81479 | Unlisted molecular pathology procedure | 0% | 25 | $0.00 |
| 81291 | 0% | 12 | $0.00 | |
| 87481 | 0% | 14 | $0.00 | |
| 81355 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRAY, KEITH (OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Leannah Investment Partners, LTD | Frisco, TX | $264K |
| Beta Biosciences, LLC | Kansas City, MO | $55K |
| Kingdom Health Laboratory LLC | Dallas, TX | $19K |
| Global Reach Labs, LLC | Denver, CO | $408.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.